Preventing HPV-related cancers in people living with HIV in California, Mexico, and Puerto Rico
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations
This program will test new, less-invasive screening methods to find and treat early cervical and anal precancers in people living with HIV in Mexico and Puerto Rico (with coordination from California).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11400868 on NIH RePORTER |
What this research studies
If you join, you would be screened using updated methods such as liquid-based Pap testing, point-of-care HPV genotyping, tests for HPV oncoproteins, and DNA methylation markers to spot high-grade precancers earlier. The program plans to screen about 4,000 women with HIV for cervical precancer and about 1,000 men with HIV who have sex with men for anal precancer, and to offer follow-up care and treatment in connected studies. The approach is to use a sensitive initial test followed by a more specific test to reduce unnecessary procedures while still catching dangerous lesions. Local clinics in Mexico and Puerto Rico will run the screening with academic coordination from UCSF.
Who could benefit from this research
Good fit: Ideal participants are adults living with HIV—particularly women in Mexico and Puerto Rico for cervical screening and HIV-positive men who have sex with men for anal screening—who are willing to attend clinic visits for screening and follow-up.
Not a fit: People without HIV, minors, or those who cannot attend participating clinics in Mexico or Puerto Rico are unlikely to be eligible or benefit from this program.
Why it matters
Potential benefit: If successful, this work could lead to earlier, more accurate, and less-invasive detection and treatment of HPV-related precancers in people living with HIV, lowering cancer risk.
How similar studies have performed: HPV genotyping and cytology are established screening tools, but combining point-of-care genotyping with oncoprotein and methylation markers in HIV-positive populations is newer and less well tested in Latin America and the Caribbean.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Palefsky, Joel Michael — University of California, San Francisco
- Study coordinator: Palefsky, Joel Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.